Literature DB >> 1350506

Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype.

C F Rochlitz1, H Lobeck, S Peter, J Reuter, B Mohr, E de Kant, D Huhn, R Herrmann.   

Abstract

Overexpression of p170 glycoprotein, the product of the multiple drug resistance (mdr) gene, has been associated with resistance to various cytotoxic drugs used in the treatment of human neoplasms. Normal renal epithelial cells express p170 as a function of their secretory capacity. Because renal cell carcinomas (RCC) respond poorly to chemotherapeutic regimens, p170 expression was studied in primary RCC. Such expression was measured in 40 human RCC and normal kidney tissues using immunohistochemical staining with the monoclonal antibody C-219. Staining intensities of the whole tumor and of different areas of the cryostat sections were transformed into digital numbers using an algorithm designed for this purpose. In most tumors, an inhomogeneous staining pattern and a correlation between grade of differentiation and C-219 immunoreactivity was observed. A comparison of the tumors according to their histopathologic subtypes showed clear differences. The means (range) of the staining intensities of the different types of RCC: clear cell carcinoma Grade 1 (n = 3), 2.0 (2.0 to 2.0); clear cell carcinoma Grade 2 (n = 19), 0.8 (0.0 to 2.9); clear cell carcinoma Grade 3 (n = 5), 0.1 (0.0 to 0.2); tubular carcinoma (n = 4), 2.0 (2.0 to 3.0); anaplastic carcinoma (n = 8), 0.05 (0.0 to 0.2); oncocytoma (n = 1), 0.0 (0.0 to 0.0); and normal kidney (n = 40), 0.5 (0.0 to 2.0). The differences between anaplastic, clear cell, and tubular carcinoma were significant (P less than 0.001 by Kruskal-Wallis test). In addition, the difference between the three subgroups of clear cell carcinoma was significant (P less than 0.01). It was concluded that the histopathologic subtypes of RCC correlate with the degree of mdr gene expression, as determined by staining with the C-219 monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350506     DOI: 10.1002/1097-0142(19920615)69:12<2993::aid-cncr2820691222>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases.

Authors:  E de Kant; I Heide; C Thiede; R Herrmann; C F Rochlitz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma.

Authors:  Y I Yu; Wei Wang; Lei Song; Wentao Hu; Chi Dong; Hailong Pei; Guangming Zhou; Zhongjin Yue
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

3.  Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.

Authors:  Carolina Muriel; Emilio Esteban; Norberto Corral; Paula J Fonseca; María Luque; José Pablo Berros; Yolanda Fernández; Pilar Blay; Joaquín Fra; Noemí Villanueva; Miguel Sanmamed; Pablo Pardo; Marta Izquierdo; José María Vieitez; Enrique Estrada; Ángel J Lacave
Journal:  Clin Transl Oncol       Date:  2010-08       Impact factor: 3.405

4.  99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99mTc-MIBI uptake and P-glycoprotein expression in tumour tissue.

Authors:  E Derebek; Z Kirkali; A S Dogan; B Degirmenci; M Yilmaz; E Igci; K Yorukoglu; I Kovanlikaya; H Durak
Journal:  Eur J Nucl Med       Date:  1996-08

Review 5.  The value of sestamibi single-photon emission computed tomography/computed tomography in differentiating and staging renal cell carcinomas: A systematic review.

Authors:  Abdalla Ali Deb; Ayman Agag; Naufal Naushad; Rajbabu Krishnamoorthy; Hosam Serag
Journal:  Curr Urol       Date:  2022-02-17

Review 6.  Antibodies in the study of multiple drug resistance.

Authors:  Y Heike; T Tsuruo
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

7.  PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia.

Authors:  C F Rochlitz; E de Kant; A Neubauer; I Heide; R Böhmer; J Oertel; D Huhn; R Herrmann
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

8.  Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma.

Authors:  Steven P Rowe; Michael A Gorin; Jennifer Gordetsky; Mark W Ball; Phillip M Pierorazio; Takahiro Higuchi; Jonathan I Epstein; Mohamad E Allaf; Mehrbod S Javadi
Journal:  Clin Nucl Med       Date:  2015-04       Impact factor: 7.794

9.  Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.

Authors:  Naomi Walsh; Annemarie Larkin; Susan Kennedy; Lisa Connolly; Jo Ballot; Wei Ooi; Giuseppe Gullo; John Crown; Martin Clynes; Lorraine O'Driscoll
Journal:  BMC Urol       Date:  2009-06-24       Impact factor: 2.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.